Italian Observational Study on CAR-T Therapy for Lymphoma

Recruiting Observational Study
Diffuse Low Grade B-Cell Lymphoma Primary Mediastinal Large B-cell Lymphoma (PMBCL) Mantle Cell Lymphoma Follicular Lymphoma
No Study Drug Researchers observe your health over time — no experimental treatment is given.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
18 and older
Sex
Any
Study type
Observational
Participants needed
5,300 (estimated)
Sponsor
Paolo Corradini · Other
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial
The goal of this observational study on chimeric antigen receptor T-cell therapy is to monitor the feasibility, efficacy, toxicity and biomarkers in a real life setting. Partecipants will be asked to agree to their clinical data collection and to partecipate to the optional biological study that aims to evaluate biomarkers of toxicity and response (clinical characteristics, cytokine profile, cell…
Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: * Patients with diagnosis of DLCBL, PMBCL, MCL and FL eligible for CAR-T treatment with commercialy available products in Italy. Exclusion Criteria: * Not applicable
Contacts

Paolo Corradini, Professor

+39 02 2390 2950

paolo.corradini@istitutotumori.mi.it

CONTACT

Anisa Bermema, PhD

+39 02 2390 3146

anisa.bermema@istitutotumori.mi.it

CONTACT